2ANL | pdb_00002anl

X-ray crystal structure of the aspartic protease plasmepsin 4 from the malarial parasite plasmodium malariae bound to an allophenylnorstatine based inhibitor


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.30 Å
  • R-Value Free: 
    0.298 (Depositor), 0.267 (DCC) 
  • R-Value Work: 
    0.247 (Depositor), 0.253 (DCC) 

Starting Model: in silico
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 2ANL

Ligand Structure Quality Assessment 


This is version 1.6 of the entry. See complete history

Literature

Structure of the aspartic protease plasmepsin 4 from the malarial parasite Plasmodium malariae bound to an allophenylnorstatine-based inhibitor.

Clemente, J.C.Govindasamy, L.Madabushi, A.Fisher, S.Z.Moose, R.E.Yowell, C.A.Hidaka, K.Kimura, T.Hayashi, Y.Kiso, Y.Agbandje-McKenna, M.Dame, J.B.Dunn, B.M.McKenna, R.

(2006) Acta Crystallogr D Biol Crystallogr 62: 246-252

  • DOI: https://doi.org/10.1107/S0907444905041260
  • Primary Citation Related Structures: 
    2ANL

  • PubMed Abstract: 

    The malarial parasite continues to be one of the leading causes of death in many developing countries. With the development of resistance to the currently available treatments, the discovery of new therapeutics is imperative. Currently, the plasmepsin enzymes found in the food vacuole of the parasite are a chief target for drug development. Allophenylnorstatine-based compounds originally designed to inhibit HIV-1 protease have shown efficacy against all four plasmepsin enzymes found in the food vacuole of Plasmodium falciparum. In this study, the first crystal structure of P. malariae plasmepsin 4 (PmPM4) bound to the allophenylnorstatine-based compound KNI-764 is described at 3.3 Angstroms resolution. The PmPM4-inhibitor complex crystallized in the orthorhombic space group P2(1)2(1)2, with unit-cell parameters a = 95.9, b = 112.6, c = 90.4 Angstroms, with two molecules in the asymmetric unit related by a non-crystallographic symmetry operator. The structure was refined to a final R factor of 24.7%. The complex showed the inhibitor in an unexpected binding orientation with allophenylnorstatine occupying the S1' pocket. The P2 group was found outside the S2 pocket, wedged between the flap and a juxtaposed loop. Inhibition analysis of PmPM4 also suggests the potential for allophenylnorstatine-based compounds to be effective against all species of malaria infecting humans and for the future development of a broad-based inhibitor.


  • Organizational Affiliation
    • Department of Biochemistry and Molecular Biology, College of Medicine, University of Florida, USA.

Macromolecule Content 

  • Total Structure Weight: 75.41 kDa 
  • Atom Count: 5,330 
  • Modeled Residue Count: 654 
  • Deposited Residue Count: 654 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
plasmepsin IV
A, B
327Plasmodium malariaeMutation(s): 0 
UniProt
Find proteins for O60990 (Plasmodium malariae)
Explore O60990 
Go to UniProtKB:  O60990
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupO60990
Sequence Annotations
Expand
Reference Sequence

Small Molecules

Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
JE2

Query on JE2



Download:Ideal Coordinates CCD File
C [auth A],
D [auth B]
(4R)-3-{(2S,3S)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl}-5,5-dimethyl-N-(2-methylbenzyl)-1,3-thiazolidine-4-carboxamide
C32 H37 N3 O5 S
CUFQBQOBLVLKRF-RZDMPUFOSA-N

Biologically Interesting Molecules (External Reference) 

1 Unique

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.30 Å
  • R-Value Free:  0.298 (Depositor), 0.267 (DCC) 
  • R-Value Work:  0.247 (Depositor), 0.253 (DCC) 
Space Group: P 21 21 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 95.884α = 90
b = 112.579β = 90
c = 90.404γ = 90
Software Package:
Software NamePurpose
SCALEPACKdata scaling
MOLREPphasing
CNSrefinement

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

Revision History  (Full details and data files)

  • Version 1.0: 2006-04-04
    Type: Initial release
  • Version 1.1: 2008-04-30
    Changes: Version format compliance
  • Version 1.2: 2011-07-13
    Changes: Atomic model, Database references, Derived calculations, Non-polymer description, Structure summary, Version format compliance
  • Version 1.3: 2012-12-12
    Changes: Other
  • Version 1.4: 2017-10-11
    Changes: Refinement description
  • Version 1.5: 2024-04-03
    Changes: Data collection, Database references, Derived calculations, Refinement description, Structure summary
  • Version 1.6: 2024-11-13
    Changes: Structure summary